RPRX

33.42

0.27% 0.09

Handel nachbörslich: 33.42

Royalty Pharma Plc (RPRX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Dividendenhistorie

Schlusskurs vom Vortag:

$33.33

Offen:

$33.29

24-Stunden-Volumen:

4.55M

Relative Volume:

1.20

Marktkapitalisierung:

$14.48B

Einnahmen:

$2.27B

Nettoeinkommen (Verlust:

$1.15B

KGV:

13.11

EPS:

2.55

Netto-Cashflow:

$2.80B

1W Leistung:

+3.28%

1M Leistung:

+10.30%

6M Leistung:

+21.09%

1J Leistung:

+7.01%

1-Tages-Spanne:

$33.06

$33.67

1-Wochen-Bereich:

$32.00

$33.69

52-Wochen-Spanne:

$24.05

$33.69

Royalty Pharma Plc Stock (RPRX) Company Profile

Firmenname

Royalty Pharma Plc

Sektor

Healthcare (1169)

Branche

Biotechnology (678)

Telefon

(212) 883-0200

Adresse

110 EAST 59TH STREET, NEW YORK, NY

Mitarbeiter

Twitter

Nächster Verdiensttermin

2025-02-11

Neueste SEC-Einreichungen

RPRX's Discussions on Twitter

Vergleichen Sie RPRX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RPRX Royalty Pharma Plc	33.42	14.48B	2.27B	1.15B	2.80B	2.55
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-06-03	Herabstufung	UBS	Buy → Neutral
2022-06-14	Fortgesetzt	UBS	Buy
2022-05-13	Eingeleitet	Scotiabank	Sector Outperform
2022-04-27	Eingeleitet	Goldman	Buy
2022-04-14	Hochstufung	JP Morgan	Neutral → Overweight
2022-04-06	Fortgesetzt	Morgan Stanley	Overweight
2021-10-29	Hochstufung	Citigroup	Neutral → Buy
2021-07-30	Eingeleitet	Tigress Financial	Buy
2020-11-09	Hochstufung	UBS	Neutral → Buy
2020-07-14	Eingeleitet	Evercore ISI	In-line
2020-07-13	Eingeleitet	BofA Securities	Buy
2020-07-13	Eingeleitet	Citigroup	Neutral
2020-07-13	Eingeleitet	Cowen	Outperform
2020-07-13	Eingeleitet	Goldman	Neutral
2020-07-13	Eingeleitet	JP Morgan	Neutral
2020-07-13	Eingeleitet	Morgan Stanley	Equal-Weight
2020-07-13	Eingeleitet	SunTrust	Buy
2020-07-13	Eingeleitet	UBS	Neutral

Alle ansehen

Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten

10:50 AM

Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by Bryn Mawr Capital Management LLC - MarketBeat

10:50 AM

Feb 20, 2025

Baillie Gifford & Co. Sells 1,987,975 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Feb 20, 2025

Royalty Pharma (NASDAQ:RPRX) Hits New 52-Week HighHere's What Happened - MarketBeat

Feb 20, 2025

Van ECK Associates Corp Increases Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Feb 20, 2025

Feb 19, 2025

Ex-Dividend Reminder: Royalty Pharma, Piedmont Office Realty Trust and Western Asset Diversified Income - Nasdaq

Feb 19, 2025

(RPRX) Trading Signals - Stock Traders Daily

Feb 19, 2025

Feb 18, 2025

Allspring Global Investments Holdings LLC Boosts Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Feb 18, 2025

Feb 16, 2025

Royalty Pharma (RPRX) to Release Quarterly Earnings on Thursday - MarketBeat

Feb 16, 2025

Feb 15, 2025

Sumitomo Mitsui Trust Group Inc. Reduces Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Feb 15, 2025

abrdn plc Sells 14,685 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Feb 15, 2025

Royalty Pharma (NASDAQ:RPRX) Issues Quarterly Earnings Results, Beats Estimates By $0.16 EPS - MarketBeat

Feb 15, 2025

Feb 14, 2025

Royalty Pharma’s Internalization Strategy: Navigating Risks and Uncertainties Ahead of 2025 Transition - MSN

Feb 14, 2025

Feb 13, 2025

Royalty Pharma's Strong Portfolio Growth and Manager Acquisition Boost Long-Term Outlook - Morningstar

Feb 13, 2025

Royalty Pharma targets $3B share buyback and projects 4-9% growth in 2025 portfolio receipts - MSN

Feb 13, 2025

Dechert advises Royalty Pharma on lupus drug funding - ICLG.com

Feb 13, 2025

Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Lecap Asset Management Ltd. - MarketBeat

Feb 13, 2025

Royalty Pharma announces R&D funding collaboration with Biogen - TipRanks

Feb 13, 2025

Feb 12, 2025

Royalty Pharma: Delivering Growth With A Positive Story Ahead (NASDAQ:RPRX) - Seeking Alpha

Feb 12, 2025

Royalty Pharma Earnings: Solid Growth; Diverse Portfolio Supports Positive Long-Term Outlook - Morningstar

Feb 12, 2025